Documente Academic
Documente Profesional
Documente Cultură
Original Articles
Abstract
Objectives: The objective was to explore the effect of a Japanese energy healing method known as Johrei on the
viability and proliferation of cultured human cancer cells in vitro.
Design: A randomly selected 96-well plate or a culture dish of various types of human cancer cell lines in culture
were exposed to Johrei treatment. For comparison purpose, an equal number of untreated or volunteer-treated
cultures were chosen as the control group. Johrei treatment was repeatedly performed at appropriate time
intervals over the course of the experiments. Cell viability was examined by a colorimetric assay with a Cell
Counting kit. Morphological changes were analyzed by phase-contrast and time-lapse microscopy. Cell proliferation and early and late stages of cell death were also determined with the use of a bromodeoxyuridine
(BrdU) cell proliferation assay kit and an Annexin V-FLUOS Staining kit, respectively.
Outcome measures: Quantitative data were presented as means standard deviation. The outcome measures
were the differences in viable cell numbers that remained under healing practice versus control conditions, and
the statistical significance of differences in their mean values was assessed.
Results: The viability loss of cultured human cancer cells in the Johrei group was significantly higher than that of
either of the control groups, despite the fact that the responsiveness to Johrei varied with different cancer cell
types. The proliferation rate of gastric cancer cells exposed to Johrei treatments for 72 hours was more significantly decreased compared with that of the untreated cells, whereas the extent of dying and/or dead cells in the
Johrei group was more profound than that of the untreated cells.
Conclusions: These results provide evidence that Johrei treatment induces the viability loss of various cancer cells
in vitro, mainly due to the increased cell death and the decreased proliferation.
Introduction
Proteolysis Research Laboratory, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan.
*These authors contributed equally to this work.
221
222
Despite little scientific evidence showing the existence of
Johrei energy, it was hypothesized that if its purported universal healing energy may be transmitted to the targets
through the hand of the Johrei practitioner, it may directly
interact with cells in culture, thereby leading to particular
alterations of their structure or function. In this study, the
culture system of various human cancer cell lines was utilized and the effect of Johrei treatment on the viability, proliferation, and death of the cultured cancer cells were
investigated.
Materials and Methods
Participants
The Johrei healing method was performed by 6 trained
Johrei practitioners who were qualified by the Japanese Johrei
Society Sekai Kyusei Kyo Izunome. The mean age of these
practitioners was 54.1 years, with a range of 4063 years. All
of the practitioners had more than 10 years experience
treating people with Johrei. They concentrated on the transmission of Johrei healing energy to cultures by means of
ABE ET AL.
Ohikari, a symbolic tool given to the practitioner qualified to
deliver this energy. Cancer cells seeded in 96-well plates or
l-dishes (ibidi, Martinsried, Germany) at appropriate densities were exposed to twice-daily Johrei healing treatments of
15 minutes (total 30 minutes per day) from approximately
15 cm away. The experiments took place over a period of 3 or
4 days. An equal number of unexposed plates and dishes
were standing very far apart from the practitioners in the
same laboratory and served as the control group. In some
experiments, 6 volunteer operators who had no experience
treating people with any energy healing methods and who
did not wear Ohikari were chosen as another control group.
During healing sessions, each member of the volunteer
group was asked to treat cell cultures in the same way as the
practitioners did. In experiments in Figure 1, each member in
both groups was given separate plates.
Culture conditions
A human gastric carcinoma cell line (AGS) was obtained
from DS Pharma Biomedical Co. (Osaka, Japan). The human
uterine cervix epithelioid carcinoma cell line HeLa, the
223
Mouse
Cell line
Susceptibility to Johrei
AGS
U937
HeLa
PC-3
ALVA-41
PPC-1
B16
Gastric cancer
Malignant lymphoma
Uterine cervix epitheloid carcimona
Prostate carcinoma
Prostate carcinoma
Prostate carcinoma
Melanoma
+++
++
+++
+
++
+
++
Each cultured cell was seeded in a 96-well plate in a volume of 100 lL at optimal density (human gastric carcinoma cell line [AGS], 2000
cells/well; HeLa and U937, 1500 cells/well; ALVA-41, PPC-1 and PC-3, 500 cells/well; mouse B16 melanoma, 800 cells/well) and cultured in
the same medium at 37C for 72 hours in a 5% CO2 incubator. During the incubation, each plate of cultured cells was subjected to twice-daily
15-minute Johrei healing-intention treatments. An equal number of unexposed cultures that were not treated by either the practitioners or the
volunteer operators were chosen as controls and processed under the same conditions as the Johrei group. Based on the ratio of the viable cell
number between the Johrei group and the control group, the relative responsiveness of each cell type to Johrei treatment was expressed as the
ratio to that of AGS cells and classified into three groups: + , low responsiveness ( < 40% of that for AGS cells); + + , moderate responsiveness
(40%80%); + + + , high responsiveness (more than 80%).
human malignant lymphoma U937, and mouse B16 melanoma cells were from RIKEN BioResource Center (Tsukuba,
Japan). The human prostate carcinoma cell line PC-3 was
obtained from Human Science Research Resources Bank
(Tokyo, Japan). Two (2) human prostate carcinoma cell lines
(ALVA-4116 and PPC-117) were kindly provided by J.Y. Bahk
(Gyeogsang National University, Korea) with the permission
of their original developers. Each of the cell lines was incubated at 37C for 24 hours in Dulbeccos modified Eagles
medium supplemented with 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 lg/mL) in a 5%
CO2 incubator. Then the cells were seeded in a 96-well plate
in a volume of 100 lL at an appropriate density (AGS, 2000
3000 cells/well; HeLa and U937, 10001500 cells/well;
ALVA-41, PPC-1 and PC-3, 5001000 cells/well; B16 melanoma, 8001500 cells/well) and cultured in the same medium
at 37C for *96 hours in a 5% CO2 incubator. These plates
were randomized to the Johrei and control groups. Each plate
of the Johrei group was subjected to twice-daily Johrei application for 15 minutes. An equal number of untreated plates
were allowed to stand far apart from the practitioners in
the same laboratory and served as the control (Table 1,
Figs. 26). As another control group, each of the volunteer
operators treated an equal number of plates in the same way
as the practitioners did.
Time-lapse microscopy
For a time-lapse analysis, AGS cells seeded in a l-dish and
cultured at 37C for 24 hours in a 5% CO2 incubator were
transferred to a time-lapse microscope (Olympus IX81, Tokyo,
Japan) equipped with a heated stage, a 5% CO2 incubation
chamber, and a Plexiglas (acrylic plastic) environment
chamber. Johrei treatments were administered 3 times a day for
a total of 45 minutes (15 minutes for each) toward the incubation chamber from a short distance (Fig. 7B). The experiments
took place over a period of 3 days. An untreated dish exposed
to neither the practitioners nor the volunteers was incubated in
the same way (Fig. 7A). Live cells were observed under the
Olympus IX81 microscope with differential interference contrast objectives (10X) and the images were collected with a
224
ABE ET AL.
225
FIG. 4. Morphological assessment of Johrei-treated human gastric cancer AGS cells and the untreated cells by differential
interference contrast microscopy. The cultured cells were seeded in a l-dish in a volume of 2 mL at a density of 4500 (A) and 6000
cells/dish (B). The cells were exposed to twice-daily Johrei treatments of 15 minutes for 72 hours. A Johrei practitioner was switched
every 24 hours with the other team member. An equal number of the untreated cells in culture were chosen as the control group
and processed under the same conditions as the Johrei group. Photographs represent the representative results from experiments
performed with five independent pairs of AGS cells. Magnification 100.
the untreated cells (Fig. 3A and B). Moreover, when AGS
cells were exposed to twice-daily 15-minute healing intention
treatments by 6 volunteer operators chosen as another control group, the number of viable AGS cells was not significantly changed by the treatment of each of the volunteer
operators (Fig. 1A, B). However, as exceptional instances, the
number of viable cells was significantly decreased at 1 day
after the treatment by the volunteer operator A and inversely
increased at 2 days after the treatment by the volunteer operators C and F and at 3 days after the treatment by the
volunteer operator E.
Morphological assessment
Morphological analysis revealed that the number of AGS
cells in the Johrei group at 72 hours after incubation was
FIG. 5. A cell proliferation assay of Johrei-treated and -untreated human gastric cancer AGS cells with the use of a BrdU assay
kit. The cultured cells were seeded in a 96-well plate in a volume of 100 lL at a density of 3000 cells/well and then incubated at
37C for 24 hours in a CO2 incubator. Then, the cells were exposed to twice-daily 15-minute Johrei treatments. An equal number
of untreated cells in culture were chosen as the control group and processed under the same conditions as the Johrei group. BrdU
was added to the cultured cells at 24 and 72 hours after the initial treatment and further incubated at 37C for 16 hours in a CO2
incubator. After fixation, amounts of the BrdU incorporated into the cells were quantified with the use of anti-BrdU detection
antibody. Lane 1, control; lane 2, Johrei practitioner A; lane 3, Johrei practitioner B; lane 4, Johrei practitioner C. Data are the
means standard deviation of values for three independent experiments, and 24 96-well plates were used in each experiment.
*p < 0.05, **p < 0.01, and ***p < 0.001, versus the corresponding values for the control group.
226
ABE ET AL.
FIG. 6. A quantitative cell death analysis of Johrei-treated and -untreated human gastric cancer AGS cells with the use of an
Annexin V-FLUOS Staining kit. Cultured AGS cells exhibited higher rates of cell death with Johrei treatments. The cells
cultured for 72 hours in a l-dish were subjected to quantitative cell death analysis with the use of an Annexin V-FLUOS
Staining kit for detecting early (yellow arrows) and late stages of cell death (red arrows). An equal number of untreated cells
in culture were chosen as the control group and processed under the same conditions as for the Johrei group. Other details are
the same as described in Fig. 4. The relative ratio of dying and/or dead cells to viable cells is significantly low in untreated
cells (A), whereas that ratio is extremely high in Johrei-treated cells (B). The data represent the representative results from
experiments with five independent pairs of AGS cells. Magnification 100.
FIG. 7. Time-lapse microscopy analysis of human gastric cancer AGS cells. AGS cells were seeded in a l-dish (35-mm
diameter) in a volume of 2 mL at a density of 4500 and incubated at 37C for 24 hours in a CO2 incubator. Then the dish was
transferred from the incubator to a time-lapse microscope equipped with a heat stage and incubation chamber. Johrei
treatments were administered 3 times a day for a total of 45 minutes (15 minutes for each) toward the incubation chamber
from a short distance (B). An equal number of untreated cells in culture were chosen as the control group and processed
under the same conditions as the Johrei group (A). To monitor the progression of proliferation of AGS cells, time-lapse
microscopy with differential interference contrast objectives (10 ) was performed. Images were collected with a cooled CCD
video camera at 10-minute intervals for 72 hours mounted on a time-lapse imaging system and saved as image stacks and
then analyzed using MetaMorpho software. Photographs represent the representative results from experiments with five
independent pairs of AGS cells and are shown as images of every 3.13 hours.
227
228
Meanwhile, it was revealed that the viability loss of AGS
cells induced by the alternate intention of the practitioners
was also induced by each of the practitioners without
switching with the team members. Interestingly, the extent of
the viability loss of AGS cells appeared to vary with each of
the Johrei practitioners. The viability loss of AGS cells by
Johrei treatments was further substantiated by morphological
analysis with the use of differential interference contrast
microscopy and time-lapse microscopy. Strikingly, the results with time-lapse microscopy clearly demonstrated that
the viability loss of the cells by Johrei treatments was apparent after 24 hours of incubation.
Next, the possible mechanism for the viability loss of AGS
cells by repeated Johrei treatments was investigated by both
cell proliferation and death assays with the use of a BrdU
assay kit and an Annexin V-FLUOS Staining kit, respectively.
The extent of proliferation was apparently decreased at 72
hours after Johrei treatments compared with untreated cells.
By contrast, the number of dying and/or dead cells was
markedly increased in Johrei-treated cells compared with untreated cells. The results strongly suggest that the decrease in
viable AGS cells in the Johrei group is mainly due to the reduced proliferation and the increased cell death. Considering
that the practitioners applied Johrei to cancer cells only with
the intention of doing transmission of its healing energy and
that they were not informed about the type (either normal or
abnormal cells) and nature (malignancy) of cells used until the
end of the said experiment, they are unlikely intending either
healing or killing to have occurred. It is also assumed that
the pleiotropic, beneficial influences of Johrei healing energy
might be complex because it dynamically interacts with various cellular molecules through regulatory, buffering, and
feedback mechanisms. At present, it is not clear how Johrei
treatment induces the viability loss of cancer cells, but the
authors believe that the underlying mechanism will be addressed in a subsequent work.
Conclusions
In vitro studies using various human cancer cell lines indicate
that Johrei treatment induces the viability loss of these cells,
which is associated with increased cell death and decreased
proliferation. The results may support the suggestive value of
Johrei practice for maintaining good health. To better understand the beneficial efficacy of Johrei in human health, further
studies are needed to elucidate whether and how Johrei treatment affects the viability of normal human cells in culture.
Disclosure Statement
No competing financial interests exist.
References
1. Brathovid A. A pilot study: Reiki, for self-care of nurses and
health-care providers. Hollist Nurs Pract 2006;20:95101.
2. Crawford S, Leever VW, Mahoney SD. Using Reiki to decrease memory and behavior problems in mild cognitive
impairment and mild Alzheimer disease. J Altern Complement Med 2006;12:911913.
3. Rubick B, Brooks AJ, Schwartz GE. In vitro effect of Reiki
treatment on bacterial cultures: Role of experimental context
ABE ET AL.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.